| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2015-10-20 | Evotec (Germany) Beyond Batten Disease Foundation (USA - TX) | juvenile Batten disease or juvenile neuronal ceroid lipofuscinosis | R&D collaboration |
Rare diseases - Neurodegenerative diseases - Genetic diseases | R&D agreement | |
| 2015-10-20 | RXi Pharmaceuticals (USA - MA) Biogazelle (Belgium) | lncRNAs | collaboration |
Collaboration agreement | ||
| 2015-10-20 | AstraZeneca (UK) | manufacturing and packaging facility in Kaluga, Russia | opening of new premises |
Opening of new premises | ||
| 2015-10-20 | Kite Pharma (USA - CA) National Institutes of Health (NIH) (USA) | T Cell Receptor (TCR)-based product candidates directed against MAGE A3 and A3/A6 antigens | tumors expressing MAGE | licensing |
Cancer - Oncology | Licensing agreement |
| 2015-10-20 | Domainex (UK) Imperial College London (UK) | MAP4K4 | myocardial infarction | R&D |
Cardiovascular diseases | R&D agreement |
| 2015-10-19 | Janssen Biotech, a J&J company (USA - NJ) Nuevolution (Denmark) | collaboration |
Cancer - Oncology - Infectious diseases - Inflammatory diseases | Collaboration agreement | ||
| 2015-10-19 | BioTime (USA - CA) | nomination |
Regenerative Medicine | Nomination | ||
| 2015-10-19 | Sigma-Aldrich (USA - MO) Wellcome Trust Sanger Institute (UK) | Sanger Institute's arrayed lentiviral CRISPR library | collaboration |
Technology - Services | Collaboration agreement | |
| 2015-10-16 | Celgene (USA - NJ) Mesoblast (Australia) | mesenchymal lineage adult stem cell product candidates | acute graft-versus-host disease (GVHD), certain oncologic diseases, inflammatory bowel diseases, and organ transplant rejection. | licensing equity placement |
Cancer - Oncology - Rare diseases - Inflammatory diseases - Transplantation | Licensing agreement |
| 2015-10-15 | AstraZeneca (UK) Peregrine Pharmaceuticals (USA - CA) | bavituximab and durvalumab (MEDI4736) | solid tumors, non-small cell lung cancer | clinical research |
Cancer - Oncology | Clinical research agreement |
| 2015-10-15 | Delcath Systems (USA - NY) | nomination |
Cancer - Oncology | Nomination | ||
| 2015-10-15 | Ablynx (Belgium) Taisho Pharmaceutical (Japan) | ozoralizumab | rheumatoid arthritis | development licensing commercialisation |
Autoimmune diseases – Inflammatory diseases - Rheumatic diseases | Licensing agreement |
| 2015-10-15 | Nabriva Therapeutics (Austria) | nomination |
Infectious diseases | Nomination | ||
| 2015-10-14 | CEVEC Pharmaceuticals (Germany) | nomination |
Technology - Services | Nomination | ||
| 2015-10-14 | Nabriva Therapeutics (Austria) | nomination |
Infectious diseases | Nomination | ||
| 2015-10-14 | Scancell Holdings (UK) | Cancer - Oncology | Nomination | |||
| 2015-10-14 | Merck KGaA (Germany) | brand identity |
Establishment of a new subsidiary in the EU | |||
| 2015-10-14 | Bind Therapeutics (USA - MA) | nomination |
Cancer - Oncology | Nomination | ||
| 2015-10-14 | Isarna Therapeutics (Germany) Autotelic (USA - CA) | trabedersen | product acquisition |
Product acquisition | ||
| 2015-10-14 | ProBioGen (Germany) Zymeworks (Canada) | GlymaxX® Antibody Glyco-Engineering technology | Technology - Services | Licensing agreement |
